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Abstract
Introduction: Pigment epithelium-derived factor (PEDF) is a multifunctional protein
with  anti-angiogenic,  antioxidant  and  anti-inflammatory  properties.  PEDF  is
involved in the pathogenesis of diabetic retinopathy, but its exact role in diabetic
kidneys remains unclear. P78-PEDF is an active peptide sequence consisting of
44 amino acids with biological activity similar to that of PEDF. The present study
aimed to investigate whether PEDF can alleviate renal damage in type 2 diabetic
nephropathy mice by inhibiting macrophage infiltration.
Material and methods: The db/db mice were randomly divided into a diabetes PEDF
intervention group (DM-P78-PEDF), a diabetes empty carrier intervention group
(DM-Vehicle),  and  a diabetes  mellitus  group  (DM).  Subsequently,  they  were
injected subcutaneously P78-PEDF (0.3 μg/g/d) and PBS for 6 weeks. The ratio
of  kidney  weight  to  body  weight  was  observed  in  the  mice. An  automatic
biochemical analyser was used to determine fasting blood glucose (GLU), blood
urea nitrogen (UREA), serum creatinine (CREA), and haemoglobin (Hb) content.
Histological  and  ultrastructural  pathological  changes  in  the  kidneys  were
examined through H&E and PAS staining. Kidney tissue levels of interleukin-1β
(IL-1β), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and interferon
gamma  (IFN-γ)  were  determined  by  ELISA. Expression  of  the  macrophage
infiltration and typing as well as that of PEDF, NF-κB, and TLR4 was evaluated
in the kidneys.
Results: PEDF was located in glomeruli,  and the expression of PEDF protein and
mRNA in  the  kidney of  diabetic  mice  declined  significantly.  Compared  with
diabetic  mice  treated  with  vehicle,  continuous  infusion  of  P78-PEDF  could
reduce  blood  urea  nitrogen,  serum  creatinine  (CREA),  renal  macrophage
recruitment,  inflammatory cytokines,  and histological  changes  and restore  the
expression of TLR4/NF-κB signalling pathway-related factors in diabetic mice.
Conclusion:  These  findings  highlight  the  importance  of  P78-PEDF  peptide  as  a
potential treatment in the occurrence and development of diabetic renal injury.
Key words: type 2 diabetes mellitus; pigment epithelium-derived factor; macrophage
infiltration; kidney injury
Introduction
Diabetes mellitus (DM) is a metabolic disorder characterized by elevated blood
glucose levels . In recent years, with the improvement of people's living standards and
the change of diet structure, the incidence rate of DM is increasing year by year and is
affecting younger people . According to incomplete statistics, DM has become the
third most challenging disease threatening human health. Persistent hyperglycaemia
will  cause  extensive  vascular  damage  and  is  expected  to  result  in  various
complications,  including diabetic  nephropathy .  Studies  have found that  intrarenal
inflammation plays an important role in the development of diabetic nephropathy, and
macrophages, as the representative of inflammatory cells, are abnormally activated
and infiltrated in glomeruli and renal interstitium in the early stage, which is one of
the key factors leading to the initiation of renal injury .
In a high glucose environment, glomerular endothelial cells and mesangial cells
are  affected  by many factors,  such as  advanced glycation end products,  oxidative
stress, and polyols, which can express a large amount of monocyte chemoattractant
protein 1 (MCP-1), interleukin-1, and other substances to recruit monocyte adhesion
and  activation,  and  finally  to  infiltrate  the  renal  interstitium  to  transform  into
macrophages and induce irreversible glomerulosclerosis . Macrophages release many
lysosomal enzymes, nitric oxide, transforming growth factor-β, and cytokines such as
tumour necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interferon-γ (IFN-γ) in the
kidney. These substances promote the occurrence and development of DM . At the
same time, macrophages can be polarized into two subtypes: classical activated M1
macrophages  and  selectively  activated  M2  macrophages.  M1 is  thought  to  cause
inflammatory and immune  injury;  M2 can  reduce  the  inflammatory response  and
exert the function of tissue repair. The proportion of M1/M2 in DM is significantly
increased,  resulting  in  renal  injury  .  Therefore,  inhibiting  the  activation  and
infiltration of macrophages in the kidney is important for the prevention and treatment
of DM.
Although  the  importance  of  inhibiting  macrophage  infiltration  has  been
recognized, current clinical interventions and efficacy of treatment are very limited .
Commonly  used  drugs  for  the  treatment  of  DM,  such  as  angiotensin-converting
enzyme  inhibitor/angiotensin  II  receptor  antagonist  (ACEI/ARB),  can  inhibit  the
activation  of  the  renin-angiotensin  system  in  the  kidney,  improve  glomerular
haemodynamics, and delay the speed of renal function injury, but they still  cannot
effectively alleviate the infiltration of macrophages in glomeruli and renal tubules .
Pigment epithelium-derived factor (PEDF) is an endogenous secretory glycoprotein
first isolated from the fine products of omental pigment epithelium secreted by human
embryonic visual cells in conditional culture. It belongs to the superfamily of non-
inhibitory serine  protease  inhibitors  .  PEDF is  widely distributed  in  lung,  kidney,
prostate,  vascular  smooth  muscle  cells,  and  other  tissues  and cells  .  It  has  many
biological  functions,  such as  inhibiting neovascularization,  inhibiting proliferation,
promoting apoptosis, inhibiting inflammatory reaction, reducing peroxidation injury
of  nerve  tissue,  enhancing  immunity,  and  so  on  .  It  has  been confirmed  that  the
expression of  PEDF is  down-regulated in  the early stage of  diabetic  nephropathy,
which is considered to be related to the increase of early permeability . At the same
time, PEDF plays a beneficial role in delaying the occurrence and development of
diabetic  nephropathy  in  the  aspects  of  anti-neovascularization,  anti-fibrosis  and
extracellular matrix accumulation, antioxidant stress, and so on .
The  molecular  weight  of  PEDF reaches  50  kDa,  which  limits  its  therapeutic
effect, and recent studies have found that some fragments of PEDF also have similar
biological activities, especially a sequence of active peptides composed of 44 amino
acids  (AA78-121;  P78-PEDF)  .  In  this  study,  we  used  a  type  2  diabetic  mouse
nephropathy model to observe the effect of an exogenous small fragment of PEDF on
macrophage infiltration in  mice,  and to  investigate  whether  small  fragment  PEDF




Twenty-four five-week-old C57BL/6 male mice (db/db mice) weighing 18–25 g
and  16  five-week-old  C57BL/6  male  mice  (db/m  mice)  weighing  18–25  g  were
selected.  The  experimental  animals  were  purchased  from  Chengdu  Dashuo
Experimental Animal Co., Ltd. (license no. SYXK 2019-189). The mice were kept in
cages with a controlled temperature and light cycle (24  and 12/12h light cycle) and℃
were provided with free access to food and water. The humidity was 40%. The present
study was approved by the Animal Care Unit and Use Committee of the Chongqing
People's Hospital, and all efforts were made to minimize animal suffering and reduce
the number of animals used.
Model preparation and animal grouping
Twenty-four  five-week-old  db/db  mice (animal  model  of  spontaneous  type  2
diabetic nephropathy) were used as a diabetic group, and 16 five-week-old db/m mice
born in the same litter were fed as a control group (Control) and normal control group
(NC); all 24 mice were fed normally. At the age of 10 weeks, the tail vein blood of
db/db mice was randomly taken to detect blood glucose (Omnitest plus blood glucose
meter, Germany). After the blood glucose was stable for 10 days, two or more random
blood glucose levels ≥ 16.7 mmol/L were considered as successful models. The db/db
mice  were  randomly divided  into  a  diabetes  PEDF intervention  group  (DM-P78-
PEDF),  a  diabetes  empty carrier  intervention group (DM-Vehicle),  and a  diabetes
mellitus group (DM). Then, the kidney tissues of the control group and DM group
were collected and stored at –80  for PEDF expression and immunofluorescence℃
assay.  The DM-P78-PEDF group received a  continuous  subcutaneous  injection  of
P78-PEDF (0.3 μg/g/d,  GL Biochem, China)  through a microperfusion  pump; the
DM-Vehicle group and NC group were also subcutaneously injected with the same
amount of phosphate buffer (PBS) through the microperfusion pump for six weeks.
After the treatment, the body weight of mice was measured and recorded, and blood
samples  of  mice  were  collected  through  the  abdominal  aorta  to  assay  the  serum
biochemical indexes. Then, the kidney tissue of mice in the NC group, DM-Vehicle
group and DM-P78-PEDF group was collected,  after  weighing the kidneys of the
three groups, and a portion of the kidney tissue samples were stored at  -80  for℃
molecular  index  determination,  while  the  remaining  samples  were  fixed  in  4%
paraformaldehyde  for  histopathological  analysis.  The kidney index was calculated
using the following formula:
(KI) = kidney mass (mg) / mouse body weight (g).
Assays of the serum biochemical indexes
The  collected  blood  samples  were  placed  at  37  for  30  min,  and  then℃
centrifuged  at  3000  rpm  for  10  min  to  collect  the  upper  serum.  The  serum
biochemical  indexes  of  fasting blood GLU, UREA, CREA, and Hb were assayed
using a HITACHI 7600-020 Automatic Biochemistry Analyzer (Shandong, China),
and  the  operation  was  carried  out  in  strict  accordance  with  the  manufacturer’s
instructions.
Haematoxylin and eosin (H&E) staining
The kidney tissues were fixed with 4% formaldehyde solution and then embedded
in paraffin. Before staining, the sections were incubated at 60℃ for 1 h, dewaxed
with xylene, and rehydrated through a series of ethanol solutions. The embedded wax
block was cut into thin slices, using a slicer, to a thickness of 3-5 µm. Finally, the
sections of kidney tissues were stained with H&E and examined by light microscopy
(Nikon,  Japan).  The  degree  of  kidney  tissue  injury  was  obtained  by  the
comprehensive evaluation of each section by histology. Images of each slide were
captured at 400 magnification.
Periodic acid-Schiff (PAS) staining
The kidney tissues were fixed with 4% formaldehyde solution and then made into
3 μm thick paraffin sections. The sections of kidney tissues were then stained with
PAS, and the glomerular segments or sclerosis were observed by light microscopy
(Nikon, Japan). Glomerular sclerosis index (GSI) was used to analyse the degree of
glomerular lesion: no pathological changes were found in glomeruli (0 points); lesion
area < 25% (1 points); lesion area 25–50% (2 points); lesion area 50–75% (3 points);
lesion  area  >  75%  (4  points),  and  each  section  was  used  to  analyse  the  400
microscopic visual field of 30 glomeruli and 20 non-glomeruli.
Enzyme-linked immunosorbent assay (ELISA)
The kidney tissue homogenate was collected for the detection of related indexes.
The expressions of IL-1β, IL-6, TNF-α, and IFN-γ in kidney tissues were detected by
ELISA.  The  operation  was  carried  out  according  to  the  kit  instructions  (Multi
Sciences,  China) with the double antibody sandwich ELISA. In brief,  the specific
anti-mice IL-1β, IL-6, TNF-α, and IFN-γ antibody were precoated on a high-affinity
enzyme-labelling  plate  to  form a  solid  phase  antibody,  and  then  it  bound  to  the
corresponding antigen in  the tissues  to  form an immune complex. After  washing,
enzyme-labelled antibodies were added to combine with the antigen in the immune
complex  to  form  the  enzyme-labelled  antibody-antigen-solid  antibody  complex.
Finally, the substrate was added for colour development, and the depth of colour was
proportional to the concentration of IL-1β, IL-6, TNF-α, and IFN-γ in the sample, to
determine the content in the sample.
Immunohistochemical staining
The kidney tissues were fixed, paraffin-embedded, sliced into serial sections, and
dewaxed. After endogenous peroxidase was blocked using 3% H2O2, the sections were
blotted  with  primary  antibody  anti-CD68  (1:100,  Abcam,  UK)  at  4  overnight,℃
followed  by  incubation  with  the  secondary  antibody  (1:200,  Zhongshan  Jinqiao,
China). Finally, sections were stained with diaminobenzidine and then counterstained
with haematoxylin.  The expression level of CD68 was quantified using integrated
optical  density values generated by Image‐Pro Plus 6.0 software.  Positive cells  in
three high-power fields (HPFs) were then counted in each section at a magnification
of 200 and the mean count of positive cells per HPF was reported.
Immunofluorescence staining
The  kidney  tissues  were  fixed,  paraffin-embedded,  sliced  into  serial  sections
(thickness 3 μm), and dewaxed. Then they were washed three times with phosphate
buffer  (PBS)  –  dripping  protease  K,  incubated  at  37  for  40  min,  and  PEDF℃
fluorescent antibody (203033, UK Abcam, 1:200) was added at 4  overnight, they℃
were rinsed three times with PBS, rabbit anti-mouse immunoglobulin with fluorescein
was added, then they were incubated at 37  for 40 min, rinsed three times with PBS,℃
and sealed with glycerol. They were observed under a fluorescence microscope and
photographed  under  an  Olympus  laser  scanning  confocal  microscope.  The  semi-
quantitative standard of immunofluorescence intensity grading refers to the current
domestic and foreign, commonly used five-point (0–4+) grading.
Flow cytometry analysis
Flow-cytometric analysis was performed following the standard protocol. The
kidney  tissue  was  ground,  the  cell  culture  medium  was  added  to  make  the  cell
suspension, and the cells were centrifuged at 300 g for 5 min at 4°C. The cells were
subjected to flow cytometry of kidney macrophages with fluorochrome-conjugated
antibodies for CD86, CD206, and F4/80 (1:100, Biolegend, USA). Isotype-matched
controls  were  used  as  negative  staining.  All  stained  cells  were  analysed  by flow
cytometry  (Cytoflex,  USA)  and  the  data  were  analysed  using  Kaluza  software
(Beckman Coulter).
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated from the  kidney  tissues using an RNA extraction kit
(Hefei Bomei Biotechnology Co., Ltd.) according to the manufacturer’s instructions.
The eligible RNA was then reverse transcribed into cDNA using a cDNA kit. After
cDNA synthesis  (Invitrogen),  mRNA expression  levels  of  PEDF,  MCP-1,  CD80,
CD86, IL-4, CD206, and CD163 were tested using the UltraSYBR Mixture. Relative
gene  expression  was  calculated  using  the  2-ΔΔCT  method  and  normalized  against
GAPDH. qRT-PCR reaction conditions were as follows: initial denaturation at 95℃
for 10 minutes, followed by denaturation at 95  for 10 minutes, annealing at 60℃ ℃
for 10 minutes, and extension at 72  of 10 minutes for 45 cycles. The CT value was℃
recorded. The used primers are listed in Table 1.
Table  1.  The  primer  sequences  used  in  quantitative  real  time-polymerase  chain
reaction (qRT-PCR) for specific mRNA amplification












The protein expressions of PEDF, TLR4, and NF-κB p65 in kidney tissues were
detected by western blotting analysis.  For  the determination of  protein expression
levels, protein samples were extracted from kidneys homogenized in RIPA buffer with
the  addition  of  Protease  Inhibitor  Cocktail  (Solarbio,  China).  Then  the  protein
concentration was quantified with the BCA protein assay (Solarbio, China). Proteins
were then separated by 10% SDS-PAGE and transferred onto PVDF membranes, and
anti-PEDF (sc-390172) antibody, anti-TLR4 (sc-293072) antibody, and anti-NF-κB
p65 (sc-8008) antibody (Santa  Cruz Biotechnology,  USA) were  used for  immune
reaction;  β-actin or Lamin B was used as a loading control. The membranes were
washed three times with TBST buffer for 10 min each time, followed by incubation
with the secondary antibody. The polyvinylidene fluoride film was removed, and the
film was obtained using the chemiluminescence method. The A value of the target
band was analysed using Quantity One gel imaging software, and the ratio of the A
value of the target band to the β-actin or Lamin B band was considered as the relative
expression of the target protein, and the number of repetitions was 
three.
Statistical analysis 
The data were statistically analysed using SPSS 20.0 software (IBM Corp.). All
data results are tested by normal distribution first. After verification of a normal or
non-normal  distribution  by  the  Shapiro-Wilk  test,  two-tailed  Student’s  t-test  and
ANOVA of  Tukey's post  hoc  was  performed  to  analyse  the  variables  of  normal
distribution. When data were not normally distributed it was log-transformed. For all
the analyses, p < 0.05 was considered to indicate a statistically significant difference.
Results
Expression of PEDF in the kidney tissue of diabetic mice
We first measured the expression of PEDF in diabetic kidney tissue. The data
showed that the mRNA (Fig. 1A) and protein (Fig. 1B, C) expression of PEDF in
diabetic kidneys was significantly lower than that in the control group (p  < 0.01).
Next, we used PEDF-specific antibody to identify the expression of PEDF in mouse
kidneys (Fig. 1D). Immunofluorescence staining results showed that PEDF expression
was mainly distributed in glomeruli, and there were obvious red target molecules in
glomeruli, i.e. PEDF distribution. The above results indicated that the expression of
PEDF in diabetic kidneys was markedly decreased, and the expression was distributed
in glomeruli.
Figure  1.  Expression  of  pigment  epithelium-derived factor (PEDF)  in  the  kidney
tissue of diabetic mice.  A. Relative mRNA expression of PEDF; B. Relative protein
expression of  PEDF;  C. PEDF protein band;  D.  Immunofluorescence staining  for
PEDF on a representative kidney section in mice. The data are expressed as the mean
± standard deviation (SD). Compared with the control group, **p < 0.01
Protective  effect  of  PEDF  on  renal  function  in  mice  with  type  2  diabetic
nephropathy
Due to  the  significant  decrease  of  PEDF in  diabetic  kidneys,  we questioned
whether the use of P78-PEDF peptide to restore PEDF would improve diabetic renal
injury. Toward this goal, we continuously injected P78-PEDF peptides or vehicle into
diabetic mice. The results showed that the protein expression of PEDF in the P78-
PEDF group was significantly higher than that in the vehicle group (p < 0.05; Fig. 2A,
B). Compared with NC mice, the level of GLU, UREA, CREA, and Hb and the ratio
of  kidney  weight/body  weight  were  significantly  increased  in  the  vehicle-treated
diabetic group (p < 0.05; Fig. 2C–G). Compared with vehicle-treated diabetic group,
administration of P78-PEDF peptide reduced the level of GLU, UREA, CREA, and
Hb and the ratio of kidney weight/body weight in diabetic mice (Fig. 2C–G). These
results  indicated  that  the  administration  of  P78-PEDF  peptide  reduces  the
characteristics of diabetic nephropathy.
Figure 2.  Protective  effect  of  pigment  epithelium-derived factor (PEDF) on renal
function in mice with type 2 diabetic nephropathy. A. Relative protein expression of
PEDF; B. PEDF protein band; C. Glucose (GLU) levels in serum; D. Urea (UREA)
levels in serum; E. Creatinine (CREA) levels in serum; F. Haemoglobin (Hb) levels in
serum; G. Calculated kidney index in each group; the data are expressed as the mean
± standard deviation (SD). Compared with the NC group,  *p < 0.05 and  **p < 0.01;
compared with the DM-Vehicle group, #p < 0.05 and ##p < 0.01.
Protective effect of PEDF on pathological damage of kidney tissue in mice with
type 2 diabetic nephropathy
The effect of PEDF on renal histopathology and renal inflammation in diabetic
mice was observed. H&E staining of kidney sections showed that a small number of
glomeruli were enlarged, and the structure of vascular glomeruli was blurred in the
renal cortical area of vehicle treated mice. After administration of P78-PEDF peptide,
a small number of glomerular glomeruli in the renal cortex were blurred, and there
was no hyperaemia and inflammatory cell infiltration in the interstitium (Fig. 3A).
PAS staining of kidney sections showed that glomerular cells increased and mesangial
dilatation  in  the  vehicle  treated  group.  The  glomerular  lesions  were  significantly
alleviated  after  treatment  with  P78-PEDF  peptides  (Fig.  3B).  The  increase  of
inflammatory cytokines is the main feature of DM and an important predictor of it.
Therefore, we further evaluated the anti-inflammatory effect of P78-PEDF peptides in
diabetic mice. Compared with NC group, the contents of IL-1β, IL-6, TNF-α, and
IFN-γ were significantly increased in kidney tissue in the vehicle treated mice (p  <
0.05, Fig 3D-G). Compared with vehicle group, the contents of IL-6,  TNF-α, and
IFN-γ could be inhibited in the group that was treated with P78-PEDF peptide (p <
0.05, Fig 3D-G). The results showed that the administration of P78-PEDF peptide
alleviated the pathological changes of the kidney and decreased the content of renal
inflammatory factors in diabetic mice.
Figure  3. Protective  effect  of  pigment  epithelium-derived  factor (PEDF)  on
pathological damage of kidney tissue in mice with type 2 diabetic nephropathy.  A.
Representative  micrographs  of  decalcified  distal  kidney  tissue  paraffin  sections
stained with H&E (magnification 400); B. Representative micrographs of decalcified
distal  kidney  tissue  paraffin  sections  stained  with  PAS  (magnification,400);  C.
Glomerular  sclerosis  index in  each group;  D. Interleukin  1  beta  (IL-1β)  levels  in
kidney tissue;  E. Interleukin 6 (IL-6) levels in kidney tissue;  F. Interferon gamma
(IFN-γ) levels in kidney tissue;  G.  Tumour necrosis factor alpha (TNF-α) levels in
kidney tissue; (A and B) scale bar, 50 μm; data expressed as the mean ± standard
deviation (SD). Compared with NC group, *p < 0.05 and **p < 0.01; compared with
the DM-Vehicle group, #p < 0.05 and ##p < 0.01
Effects  of  PEDF on the infiltration and typing of  macrophages in the kidney
tissue of type 2 diabetic nephropathy mice
To determine whether PEDF is the key to macrophage infiltration in DM, we
used the immunohistochemical method to show the expression of CD68 in mouse
kidneys.  Compared  with  NC  group,  the  expression  of  CD68  was  significantly
increased in kidney tissue of diabetic mice in the vehicle group (p < 0.01; Fig. 4A). In
contrast, the expression of CD68 was significantly decreased in the kidney of diabetic
mice treated with P78-PEDF peptide (p < 0.05; Fig. 4A). Flow cytometry was used to
identify  the  expression  of  F4/80+CD86+ (M1)  and  F4/80+CD206+ (M2)  in  renal
macrophages.  Compared  with  the  NC  group,  the  level  of  F4/80+CD86+was
significantly increased in renal tissue of diabetic mice in the vehicle group, and the
level of F4/80+CD206+ was markedly decreased in the vehicle group (p < 0.01; Fig.
4B). Compared with the vehicle group, the level of F4/80+CD86+ was significantly
decreased in the P78-PEDF group, and the level of F4/80+CD86+ could be increased
in the group that was treated with P78-PEDF (p < 0.05; Fig. 4B). The detection of M1
and M2 key factors by qRT-PCR. Compared with the NC group, the levels of MCP-1,
CD80, CD86, and CD163 were significantly increased in kidney tissue of diabetic
mice  in  the  vehicle  group,  while  the  levels  of  IL-4  and  CD206  were  markedly
decreased in the vehicle group (p < 0.05; Fig. 4C). Compared with vehicle group, the
expressions of MCP-1, CD80, CD86, and CD163 were significantly reduced, and the
expression of IL-4 was significantly increased, in the P78-PEDF treatment group (p <
0.05;  Fig.  4C). These results  indicate that  P78-PEDF peptide administration could
reduce the recruitment of macrophages in diabetic mice.
Figure 4. Effects of pigment epithelium-derived factor (PEDF) on the infiltration and
typing of macrophages in the kidney tissue of type 2 diabetic nephropathy mice. A.
Immunohistochemical  staining  for  macrophages  infiltrating  the  kidney.
Representative  photomicrographs  of  kidney  tissue  sections  stained  for  CD68.
Quantification of the number of CD68-positive macrophages infiltrating the kidney;
B. Flow  cytometric  analysis  of  activation  levels  of  serum  M1  (CD86)  and  M2
(CD206) macrophages; C. Relative mRNA expression of MCP-1, CD80, CD86, IL-4,
CD206,  and  CD163;  (A)  Scale  bar,  40  μm;  data  expressed  as  mean  ±  standard
deviation (SD). Compared with NC group, *p < 0.05 and **p < 0.01; compared with
the DM-Vehicle group, #p < 0.05 and ##p < 0.01
Effect  of  PEDF on  TLR4/NF-κB signalling  pathway  in  the  kidneys  of  type  2
diabetic nephropathy mice
To determine  changes  of  TLR4/NF-κB signal  pathway in  diabetic  mice  after
P78-PEDF intervention, we detected the expression levels of TLR4 and NF-κB p65.
Compared with the NC group, the protein expressions of TLR4 and NF-κB p65 were
significantly increased in the kidney tissue of mice in the vehicle group (p < 0.05; Fig.
5A, B). Compared with the vehicle group, the protein expressions of TLR4 and NF-
κB p65 in the P78-PEDF group were substantially decreased (p < 0.05; Fig. 5AB).
These  results  show  that  the  protein  level  of  related  factors  in  the  TLR4/NF-κB
pathway increased in diabetic mice,  while P78-PEDF reduced the protein level of
related factors in this pathway in diabetic mice.
Figure  5.  Effect  of  pigment  epithelium-derived  factor (PEDF)  on  TLR4/NF-κB
signalling pathway in the kidneys of type 2 diabetic nephropathy mice.  A. Protein
band and relative protein expression of TLR4;  B. Protein  band and relative protein
expression of NF-κB p65. The data are expressed as the mean ± standard deviation
(SD). Compared with NC group,  *p< 0.05 and  **p < 0.01; compared with the DM-
Vehicle group, #p < 0.05 and ##p < 0.01.
Discussion
The PEDF protein is expressed in several tissues and cell types including kidney
tissue . In this study, a small bioactive peptide of PEDF (P78-PEDF) mediates the
protective effect of renal tissue, which is characterized by the decrease of UREA,
CREA,  Hb,  histopathological  changes,  renal  macrophage  recruitment,  and  the
decrease of inflammatory cytokines in diabetes. In addition, P78-PEDF can inhibit the
protein level of related factors in the TLR4/NF-κB pathway. These findings reveal the
crucial role of P78-PEDF peptides in the pathogenesis of DM, and P78PEDF may
provide a new treatment model for patients with type 2 diabetes.
In recent years, scholars have paid increasing attention to the expression and role
of PEDF in the serum, urine, and renal tissue of patients with diabetes. Studies have
shown  that  PEDF,  as  a  protective  factor  of  diabetic  chronic  microvascular
complications, has the effects of anti-inflammatory reaction, antioxidant stress, and
protecting  vascular  endothelial  function  .  Awad  et  al.  [16] showed  that  PEDF  is
expressed mainly in the kidney vasculature,  interstitial  spaces,  glomeruli,  medulla,
and  tubular  epithelial  cells,  and  was  also  able  to  detect  PEDF  expression  in
glomerular endothelial cells cultured in vitro in a normal glucose medium, and this
effect  was  significantly  reduced  when  high-glucose  medium was  used  [17].  It  is
hypothesized  that  the  reduction  in  PEDF  may  be  associated  with  a  high-glucose
environment. At the same time, studies have confirmed that PEDF intervention can
reduce the content of TNF-α in the urine of diabetic rats, and TNF-α is considered to
be a cytokine mainly produced by monocytes and macrophages, which is an important
factor leading to the increase of renal vascular endothelial permeability and urinary
protein leakage in diabetic nephropathy . However, there are few studies investigating
whether  PEDF can directly inhibit  chemotaxis and activate MCP-1 and NF-κB of
macrophages and inhibit CD68-positive macrophages in glomeruli, and even fewer
assessing whether it can promote the transformation of the proportion of M1/M2 to
M2, to reduce the renal injury caused by inflammation. In this experiment, we used a
specific antibody to identify the expression of PEDF in the kidneys of mice. Our data
show that PEDF is expressed in glomeruli. We further questioned whether PEDF has
changed in diabetes. The data show that both PEDF protein and mRNA expression are
significantly decreased in diabetic kidneys. These data are consistent with previous
reports of reduced expression of PEDF protein and mRNA in the kidneys of diabetic
rats .
In order to examine the role of PEDF in diabetes, we continuously injected a
small bioactive peptide fragment of PEDF (P78-PEDF) into the mouse model of type
2  diabetes.  P78-PEDF  peptides  have  recently  been  identified  and  have  shown
excellent biological activity . Our data show that the renal protective effect of P78-
PEDF  peptides  is  associated  with  a  significant  reduction  of  renal  macrophage
infiltration.  The  infiltration  of  macrophages  in  glomeruli  and  interstitium and the
proliferation  of  glomerular  extracellular  matrix  (ECM)  are  important  features  of
diabetic nephropathy . MCP-1 is mainly produced by renal tubular epithelial cells and
glomerular  mesangial  cells,  and its  main function is  chemotaxis and activation of
mononuclear macrophages. Li et al.  found that MCP-1 plays an important part in the
pathogenesis  of  type  1  diabetes  by attracting  monocytes/macrophages  to  infiltrate
pancreatic islets. NF-κB is one of the important transcriptional proteins regulating the
expression of MCP-1. It has been verified that the activity of NF-κBp65 protein and
the expression of MCP-1mRNA in glomeruli increased significantly in STZ-induced
diabetic rats,  followed by macrophage infiltration,  which was positively correlated
with the number of CD68-positive macrophages. Therefore, MCP-1, NF-κB, and the
number of CD68-positive macrophages in glomeruli can be regarded as markers of
renal macrophage infiltration. Their abnormally increased expression leads directly to
renal injury . TNF-α is mainly produced by monocytes/macrophages and is related to
the increase of vascular endothelial cell permeability in diabetes mellitus . This study
confirmed the above results and showed that P78-PEDF peptide could dramatically
increase the content of IL-1β, IL-6, TNF-α, and IFN-γ and decrease the expression of
MCP-1, CD80,  CD86,  and CD163. Our data  also showed that  P78-PEDF peptide
treatment decreased the expression of TLR4 in the kidney, confirming the effect of
PEDF on macrophage inflammation by inhibiting NF-κB . It has been suggested that
the  decrease  of  PEDF may be  involved in  the  occurrence  and/or  development  of
diabetes, and some beneficial effects of P78-PEDF peptides in DM may be mediated
by macrophage infiltration.
Conclusions
Our study shows that PEDF fragment P78-PEDF has a renal protective effect in type
2 diabetes; in particular, P78-PEDF peptide reduces renal macrophage infiltration and
improves  renal  histopathology.  The results  of  this  study provide  support  for  P78-
PEDF peptide as a therapeutic method for the treatment of type 2 diabetes. The exact
efficacy of P78-PEDF peptide in the treatment  of type 2 diabetes requires further
study.
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